In this article, I am going to share my analysis of valuing Alexza after the Teva deal for commercializing ADASUVE in the U.S. was announced. The major key assumptions for Alexza and ADASUVE that I used in my analysis cover the following areas: potential U.S. market size, estimated U.S. market share, estimated market share in the Grupo Ferrer territory, transfer price per ADASUVE inhaler, revenue per ADASUVE inhaler, tiered royalty percentages, milestone payments, general & administrative expenses, research & development expenses, federal income taxes, payments to Symphony Allegro, long-term debt, weighted average cost of capital (WACC), and growth rate at terminal. I will detail each of my key assumptions below.